Nicotinamide mononucleotide (NMN) for middle-aged and older adults

Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)

This trial will test whether daily oral NMN helps middle-aged and older adults slow age-related decline and improve quality of life.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 240 (estimated)
• Ages: 39 Years to 70 Years
• Sex: All
• Sponsor: People's Hospital of Quzhou (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Quzhou, Zhejiang)
• Trial ID: NCT06592859 on ClinicalTrials.gov

What this trial studies

This is a single-center, randomized, double-blind, placebo-controlled trial comparing oral NMN to placebo in participants aged 40–50 and 60–70. The trial monitors safety and clinical measures thought to reflect biological aging while collecting biomarkers to identify who responds best. Participants are local residents of Quzhou and will be followed with scheduled visits at the enrolling hospital. The study aims to characterize patterns of efficacy across subgroups and to identify sensitive biomarkers of response.

Who should consider this trial

Good fit: Ideal candidates are generally healthy Quzhou residents aged 40–50 or 60–70 who can give informed consent, have no major recent surgery, and do not have heavy smoking, obesity, or disqualifying medical conditions.

Not a fit: People with major chronic diseases, recent major surgery, obesity (BMI >30), heavy smoking, current pregnancy or lactation, substance abuse, or recent use of certain medications/supplements may not benefit or be eligible.

Why it matters

Potential benefit: If successful, NMN could slow aspects of biological aging and improve physical function and quality of life in middle-aged and older adults.

How similar studies have performed: Preclinical studies and small early human trials of NMN have shown metabolic and safety signals, but conclusive evidence that NMN slows human aging remains limited.

Eligibility criteria

Inclusion criteria：

1. Local residents of Quzhou or living in Quzhou for over ten years.
2. age 40-50 and 60-70 years old, no major bad habits.
3. Gender unlimited.
4. in good health and has not undergone major surgery within half a year.
5. Be able to communicate well with researchers and cooperate with the work during the study.
6. Written informed consent can be signed voluntarily.

Exclusion criteria：

1. Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
2. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
3. Obesity (bmi more than 30).
4. Pregnant/lactating women.
5. Disease history:

   A) under 60 years old:
   1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
   2. coronary artery disease/myocardial infarction/clinically significant congestive heart failure.
   3. stroke/transient ischemic attack.
   4. deep vein thrombosis/pulmonary embolism.
   5. serum creatinine \> 1.5 mg/dl (male).
   6. poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \> 160 mmHg, or diastolic blood pressure \>100 mmHg)).
   7. history of active liver disease or metabolic acidosis.
   8. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
   9. severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc.
   10. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
   11. diabetes mellitus (hemoglobin \> 6.5% or fasting blood glucose \> 126 mg/dL or taking diabetes drugs or insulin treatment).
   12. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
   13. infectious diseases such as HIV, hepatitis, tuberculosis, etc.
   14. hand or lower limb disability affects normal function and life.

   B) older than 60 years:
   1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
   2. history of active liver disease or metabolic acidosis.
   3. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
   4. severe autoimmunity/inflammation, such as lupus, Crohn\'s disease, etc.
   5. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
   6. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
   7. infectious diseases such as HIV, hepatitis, tuberculosis, etc.
   8. hand or lower limb disability affects normal function and life.
6. Currently taking the following drugs regularly:

   A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin).

   C) cholinesterase inhibitors for Alzheimer\'s disease (donepezil/alicept).
7. The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.

Where this trial is running

Quzhou, Zhejiang

• People's Hospital of Quzhou — Quzhou, Zhejiang, China (Recruiting)

Study contacts

• Study coordinator: Feng Zhang

Conditions Aging; NMN